Business
Johnson & Johnson : DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSIS
Johnson & Johnson : DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s
About this update from Johnson & Johnson
[{"type":"text","content":"Home/\n DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO's NOVOSIS\n DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO's NOVOSIS\n Partnership strengthens DePuy Synthes' portfolio with a differentiated bone graft substitute containing growth factors to address unmet need across orthopaedic specialties\n May 26, 2026\n \n \n May 26, 2026\n \n Share \n FacebookX (Twitter)PinterestLinkedIn\n Copy linkRAYNHAM, Mass. - (May 26, 2026) - DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced an exclusive distribution agreement 1 with CGBIO, a biotechnology company specializing in regenerative medicine, for the development and commercialization of NOVOSIS, an advanced bone graft substitute containing growth factors, across its orthopaedic portfolio including spine, craniomaxillofacial (CMF), and trauma.\n \n \n NOVOSIS is a novel growth-factor bone graft substitute designed to address unmet needs associated with existing solutions and to support improved clinical outcomes. An investigational device exemption (IDE) study for Spine procedures has been approved and is actively enrolling in the United States to evaluate safety and effectiveness. If supported by clinical data and regulatory approval, NOVOSIS will expand treatment options within DePuy Synthes' Spine portfolio.\n \n \n \"NOVOSIS has the potential to meaningfully advance orthopaedic care as a transformative treatment option for patients,\" said Namal Nawana, Worldwide President, DePuy Synthes. \"This collaboration reflects our continued focus on strengthening our portfolio with differentiated technologies that address unmet needs and support patient care. This collaboration leverages the complementary strengths of both companies and the success of NOVOSIS in other markets as we advance clinical development and prepare for future commercialization in key markets.\"\n \n \n Under the terms of the agreement, DePuy Synthes will hold exclusive distribution rights for NOVOSIS in the United States, Canada and Australia, as well as rights of first negotiation for additional global markets.\n \n \n Johnson & Johnson and CGBIO previously entered into an exclusive distribution and promotional agreement2 for NOVOSIS in Korea, Taiwan, Thailand, India, Hong Kong and Macau...